Answer first: the top pick for a cancer patient is an FDA-approved cannabinoid medicine, prescribed and monitored by the oncology team. That group today is dronabinol (Marinol, Syndros) and nabilone (Cesamet) for chemotherapy-induced nausea and vomiting, plus cannabidiol (Epidiolex) for three rare seizure disorders. Everything else, including dispensary flower and hemp CBD, gets judged against four criteria: FDA approval status, whether the treating oncologist can see and dose it, third-party lab testing with a readable certificate of analysis, and a drug interaction review against the current regimen.
What counts as medical cannabis in the United States
Cannabis is a Schedule I substance under federal law, so "medical cannabis" is a state-law term, not a federal one. Dozens of states run programs that let a clinician certify a patient, and cancer plus its treatment side effects are qualifying conditions in most of them. That state card does not change federal law, and it does not turn the product into a medicine in the FDA sense. The distinction matters because it decides who is accountable for dosing, purity, and interactions.
Option 1: FDA-approved cannabinoid medicines (top pick)
Dronabinol is synthetic THC in a capsule or oral solution. Nabilone is a synthetic THC analog in a capsule. Both are approved for chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics; dronabinol also carries an approval for appetite and weight loss in AIDS wasting. Epidiolex is a purified, plant-derived CBD oral solution approved for Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex seizures, not for cancer symptoms.
- Pros: known potency, regulated manufacturing, a prescriber who owns the dose, and a documented side effect and interaction profile.
- Cons: narrow approved uses, THC-related effects such as sedation, dizziness, and impaired coordination, plus uneven insurance coverage and cost that varies by plan.
Best for: a patient with nausea and vomiting that has failed standard antiemetic regimens, where the oncologist is willing to add or substitute a cannabinoid.
Option 2: State-legal medical cannabis from a dispensary
- Pros: whole-plant products with THC levels above the hemp limit, a wider menu of routes such as vapor, oil, and edible, state-mandated testing for potency and contaminants in most programs, and staff who can walk through ratios.
- Cons: no FDA review, batch-to-batch variability, no standard dosing, federal illegality that touches travel, employment, firearms, and housing, and a real gap between labeled and actual THC content in some lots.
Best for: a patient in a legal state with an oncologist who knows which product is being used and has reviewed interactions, and who is not enrolled in a trial that prohibits cannabinoids.
Option 3: Hemp-derived CBD products
- Pros: federally legal when THC stays at or below 0.3 percent dry weight, no state card required, non-intoxicating for most users, and the better makers publish batch-level certificates of analysis.
- Cons: no FDA approval for cancer symptoms, limited and mixed evidence for anxiety and sleep in this population, documented mislabeling across the wider market, and the same CYP450 interaction risk that applies to any cannabinoid.
Best for: a patient who wants a low-THC option for general distress, sleep, or appetite, with the oncology team informed before the first dose.
How to read a certificate of analysis
Ask for the batch number and the matching report from an accredited lab. Check three lines: total THC, total CBD, and the contaminant panel covering pesticides, heavy metals, residual solvents, and microbials. A potency number without a contaminant panel is half a test, and a report without a batch number cannot be tied to the bottle in your hand. Check the date as well. Cannabinoid content drifts as an oil sits on a shelf, so a report older than the current lot describes the last run, not this one.
Safety, interactions, and what to tell the oncology team
Cannabinoids are metabolized in part by CYP3A4 and CYP2C9, the same enzymes that handle many chemotherapy agents, antifungals, and seizure drugs. CBD in particular can raise levels of drugs cleared by those pathways, and some chemo regimens depend on tight blood levels. Bring the actual product, the COA, and the dose to the appointment rather than a general description. Common side effects include drowsiness, dry mouth, dizziness, and lowered blood pressure. THC can worsen anxiety in some patients and affect balance, which matters for anyone at fall risk. Cannabis is not a treatment for the cancer itself, and nothing here replaces oncology care.
Choosing by situation
- Refractory chemo nausea and vomiting: ask the oncologist about dronabinol or nabilone first.
- State-legal patient with an informed oncologist: dispensary products under supervision.
- Sleep, anxiety, or appetite support with legal access and no THC tolerance: a third-party tested CBD oil at the lowest effective dose.
- Any patient in an active clinical trial: check the protocol before adding any cannabinoid.